[MO5] Mini-Oral Session 5　肝胆膵2（HCC・膵がん）
【E】

[MO5-4] Potential Roles of Gut Microbiome in Patients with Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

^○Yung-Yeh Su^1,2, Wei-Hsiang Lee^3,4, Jing-Houng Wang⁵, Hung-Wei Wang⁶, Teng-Wei Chen⁷, Bang-Bin Chen⁸, Hsiu J Ho^3,4, Tsung-Hao Liu⁹, Shu-Cheng Chou¹⁰, Bor-Rong Chen¹¹, Tsang-Wu Liu¹¹, Li-Tzong Chen^1,2,12, Chun-Ying Wu^3,4,13, Chiun Hsu^9,14,15 (1.National Institute of Cancer Research, National Health Research Institute, Tainan, Taiwan, 2.Department of Oncology, National Cheng-Kung University Hospital, Tainan, Taiwan, 3.Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan, 4.Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, 5.Department of Internal Medicine, Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, 6.Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, 7.Department of Surgery, Tri-Service General Hospital, Taipei, Taiwan, 8.Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan, 9.Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, 10.Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 11.Taiwan Cooperative Oncology Group, National Institute of Cancer Research, National Health Research Institutes, Taipei, Taiwan, 12.Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 13.College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, 14.Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan, 15.National Taiwan University Cancer Center, Taipei, Taiwan)